ATE313537T1 - Antagonisten von mcp-1 tätigkeit und deren verwendungsmethoden - Google Patents

Antagonisten von mcp-1 tätigkeit und deren verwendungsmethoden

Info

Publication number
ATE313537T1
ATE313537T1 AT02709746T AT02709746T ATE313537T1 AT E313537 T1 ATE313537 T1 AT E313537T1 AT 02709746 T AT02709746 T AT 02709746T AT 02709746 T AT02709746 T AT 02709746T AT E313537 T1 ATE313537 T1 AT E313537T1
Authority
AT
Austria
Prior art keywords
mcp
antagonists
activity
methods
Prior art date
Application number
AT02709746T
Other languages
German (de)
English (en)
Inventor
Edgardo Laborde
Louise Robinson
Fanying Meng
Brian T Peterson
Hugo O Villar
Steven E Anuskiewicz
Yoshiro Ishiwata
Shoji Yokochi
Yukiharu Matsumoto
Takuji Kakigami
Hideaki Inagaki
Takahito Jomori
Kouji Matsushima
Original Assignee
Telik Inc
Sanwa Kagaku Kenkyusho Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Telik Inc, Sanwa Kagaku Kenkyusho Co filed Critical Telik Inc
Application granted granted Critical
Publication of ATE313537T1 publication Critical patent/ATE313537T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
AT02709746T 2001-03-01 2002-02-28 Antagonisten von mcp-1 tätigkeit und deren verwendungsmethoden ATE313537T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27279201P 2001-03-01 2001-03-01
PCT/US2002/006256 WO2002070509A2 (en) 2001-03-01 2002-02-28 Antagonists of mcp-1 function and methods of use thereof

Publications (1)

Publication Number Publication Date
ATE313537T1 true ATE313537T1 (de) 2006-01-15

Family

ID=23041292

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02709746T ATE313537T1 (de) 2001-03-01 2002-02-28 Antagonisten von mcp-1 tätigkeit und deren verwendungsmethoden

Country Status (14)

Country Link
US (2) US6809113B2 (cg-RX-API-DMAC7.html)
EP (1) EP1363897B1 (cg-RX-API-DMAC7.html)
JP (1) JP4291576B2 (cg-RX-API-DMAC7.html)
KR (1) KR20040018336A (cg-RX-API-DMAC7.html)
CN (1) CN1259315C (cg-RX-API-DMAC7.html)
AR (1) AR035759A1 (cg-RX-API-DMAC7.html)
AT (1) ATE313537T1 (cg-RX-API-DMAC7.html)
BR (1) BR0207750A (cg-RX-API-DMAC7.html)
CA (1) CA2439849A1 (cg-RX-API-DMAC7.html)
DE (1) DE60208159T2 (cg-RX-API-DMAC7.html)
ES (1) ES2254653T3 (cg-RX-API-DMAC7.html)
MX (1) MXPA03007861A (cg-RX-API-DMAC7.html)
TW (1) TWI245761B (cg-RX-API-DMAC7.html)
WO (1) WO2002070509A2 (cg-RX-API-DMAC7.html)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE502928T1 (de) 2000-11-01 2011-04-15 Millennium Pharm Inc Stickstoffhaltige heterozyklische verbindungen und verfahren zu deren herstellung
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
WO2006029173A2 (en) * 2004-09-08 2006-03-16 Boys Town National Research Hospital Treatment of glomerular basement membrane disease involving matrix metalloproteinase-12
MX2007012082A (es) 2005-03-31 2007-11-20 Pfizer Prod Inc Derivados de ciclopentapiridina y tetrahidroquinolina.
WO2007066496A1 (en) * 2005-12-07 2007-06-14 Sumitomo Chemical Company, Limited Benzoylurea compound and use thereof
US7601716B2 (en) * 2006-05-01 2009-10-13 Cephalon, Inc. Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors
US7919077B2 (en) * 2006-07-24 2011-04-05 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising CCL2 and use of same for the treatment of inflammation
US20080076120A1 (en) * 2006-09-14 2008-03-27 Millennium Pharmaceuticals, Inc. Methods for the identification, evaluation and treatment of patients having CC-Chemokine receptor 2 (CCR-2) mediated disorders
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
DK2091948T3 (da) 2006-11-30 2012-07-23 Probiodrug Ag Nye inhibitorer af glutaminylcyclase
US20100303777A1 (en) * 2006-12-14 2010-12-02 Actogenix N.V. Delivery of binding molecules to induce immunomodulation
EP2481408A3 (en) 2007-03-01 2013-01-09 Probiodrug AG New use of glutaminyl cyclase inhibitors
DK2142514T3 (da) 2007-04-18 2015-03-23 Probiodrug Ag Thioureaderivater som glutaminylcyclase-inhibitorer
US8356920B2 (en) * 2007-12-12 2013-01-22 Levine Jonathan E Lighting device
WO2010068881A1 (en) * 2008-12-12 2010-06-17 Forest Laboratories Holdings Limited Novel benzodioxane and benzoxazine derivatives useful as cc chemokine receptor ligands
US8486940B2 (en) 2009-09-11 2013-07-16 Probiodrug Ag Inhibitors
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
ES2481823T3 (es) 2010-03-10 2014-07-31 Probiodrug Ag Inhibidores heterocíclicos de glutaminil ciclasa (QC, EC 2.3.2.5)
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
US8530670B2 (en) 2011-03-16 2013-09-10 Probiodrug Ag Inhibitors
EP2522341A1 (en) * 2011-05-13 2012-11-14 Tragex Pharma Pharmaceutical compositions comprising Neuropilin inhibitors, and their use for the prevention and/or treatment of angiogenic disorders and cancers
TWI742513B (zh) 2013-11-18 2021-10-11 美商弗瑪治療公司 作為bet溴域抑制劑之四氫喹啉組成物
CN106029076B (zh) 2013-11-18 2019-06-07 福马疗法公司 作为bet溴域抑制剂的苯并哌嗪组合物
US20180193003A1 (en) 2016-12-07 2018-07-12 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
WO2018112264A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
WO2018201091A1 (en) * 2017-04-27 2018-11-01 Washington University Chemokine decoy receptors of rodent gammaherpesviruses and uses thereof
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej
EP3643711A1 (en) 2018-10-24 2020-04-29 Bayer Animal Health GmbH New anthelmintic compounds
JP7482866B2 (ja) 2018-11-19 2024-05-14 ビオラ・セラピューティクス・インコーポレイテッド 生物学的治療薬による疾患処置方法およびデバイス
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1250611A (cg-RX-API-DMAC7.html) 1968-02-03 1971-10-20
IE32700B1 (en) 1968-02-03 1973-10-31 Beecham Group Ltd Penicillins
DE2131034A1 (de) * 1971-06-23 1973-01-11 Hoechst Ag Acylharnstoffe und verfahren zu ihrer herstellung
DE2652004C3 (de) * 1976-11-15 1979-09-13 Basf Ag, 6700 Ludwigshafen l-Acyl-2-arylamino-2-imidazoline, Verfahren zu ihrer Herstellung und ihre Verwendung
US4163784A (en) 1978-03-09 1979-08-07 Pfizer Inc. Heterocyclylcarbonyl derivatives of urea, agents for dissolution of gallstones
GB8528234D0 (en) 1985-11-15 1985-12-18 Wyeth John & Brother Ltd Heterocyclic compounds
JP2650055B2 (ja) 1988-11-28 1997-09-03 キヤノン株式会社 電子写真感光体
FR2672888B1 (fr) 1991-02-14 1994-02-04 Fabre Medicament Pierre Nouvelles urees et thiourees, leur preparation et leur application en therapeutique.
JP3964478B2 (ja) * 1995-06-30 2007-08-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬
WO1997024325A1 (en) 1995-12-28 1997-07-10 Takeda Chemical Industries, Ltd. DIPHENYLMETHANE DERIVATIVES AS MIP-1α/RANTES RECEPTOR ANTAGONISTS
JPH09255572A (ja) 1996-03-26 1997-09-30 Takeda Chem Ind Ltd ケモカイン受容体拮抗剤
JP4176148B2 (ja) 1996-05-20 2008-11-05 帝人ファーマ株式会社 ジアリールアルキル環状ジアミン誘導体およびその治療薬としての使用
CA2259927A1 (en) 1996-07-12 1998-01-22 Leukosite, Inc. Chemokine receptor antagonists and methods of use therefor
US6140338A (en) * 1996-07-29 2000-10-31 Banyu Pharmaceutical, Co., Ltd. Chemokine receptor antagonists
EP0927167A1 (en) 1996-08-14 1999-07-07 Warner-Lambert Company 2-phenyl benzimidazole derivatives as mcp-1 antagonists
WO1998027815A1 (en) 1996-12-20 1998-07-02 Merck & Co., Inc. Substituted aminoquinolines as modulators of chemokine receptor activity
GB9716656D0 (en) * 1997-08-07 1997-10-15 Zeneca Ltd Chemical compounds
CA2319494A1 (en) 1998-02-03 1999-08-12 Boehringer Ingelheim Pharma Kg 5-membered heterocyclic condensed benzoderivatives, the preparation thereof and their use as pharmaceuticals
AU753360B2 (en) * 1998-07-31 2002-10-17 Nippon Soda Co., Ltd. Phenylazole compounds, process for producing the same and drugs for hyperlipemia
US6316449B1 (en) * 1999-07-08 2001-11-13 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists
EP1255741A2 (en) 2000-02-01 2002-11-13 Cor Therapeutics, Inc. 2- 1H]-QUINOLONE AND 2- 1H]-QUINOXALONE INHIBITORS OF FACTOR Xa
WO2001057044A1 (en) 2000-02-01 2001-08-09 Daiichi Pharmaceutical Co., Ltd. Pyridoxazine derivatives
WO2001057003A1 (en) 2000-02-01 2001-08-09 Cor Therapeutics, Inc. 3,4-DIHYDRO-2H-BENZO[1,4]OXAZINE INHIBITORS OF FACTOR Xa

Also Published As

Publication number Publication date
EP1363897A2 (en) 2003-11-26
WO2002070509A2 (en) 2002-09-12
BR0207750A (pt) 2004-03-23
JP4291576B2 (ja) 2009-07-08
US20050054668A1 (en) 2005-03-10
US7297696B2 (en) 2007-11-20
HK1060728A1 (en) 2004-08-20
KR20040018336A (ko) 2004-03-03
EP1363897B1 (en) 2005-12-21
CN1259315C (zh) 2006-06-14
AR035759A1 (es) 2004-07-07
US6809113B2 (en) 2004-10-26
WO2002070509A8 (en) 2003-11-06
JP2004527503A (ja) 2004-09-09
DE60208159T2 (de) 2006-08-17
CA2439849A1 (en) 2002-09-12
TWI245761B (en) 2005-12-21
WO2002070509A3 (en) 2003-05-30
CN1494539A (zh) 2004-05-05
US20030105085A1 (en) 2003-06-05
ES2254653T3 (es) 2006-06-16
MXPA03007861A (es) 2004-10-15
DE60208159D1 (de) 2006-01-26

Similar Documents

Publication Publication Date Title
ATE313537T1 (de) Antagonisten von mcp-1 tätigkeit und deren verwendungsmethoden
DE60214996D1 (de) Antagonisten der mcp-1-funktion und verfahren zu deren verwendung
DE60140377D1 (de) Mch antagonisten und deren verwendung zur behandlung von fettleibigkeit
ATE374204T1 (de) Thienopyrimidinedione und deren verwendung in der behandlung von autoimmunerkrankungen
DE60239485D1 (de) Benzamid und heteroarylamid als p2x7-rezeptorantagonisten
ATE297380T1 (de) Mch antagonisten und deren verwendung zur behandlung von fettleibigkeit
AU2002360400A8 (en) Construction and use of micro-electrode arrays
ATE305468T1 (de) Chinuclidincarbamat derivate und deren verwendung als m3 antagonisten
ATE312613T1 (de) Niedrig dosierte entecavir formulierung und deren verwendung
ATE394102T1 (de) Substituierte chinazolin-derivate und deren verwendung als aurora-2-kinase inhibitoren
DE60112322D1 (de) Aminothiazole und deren verwendung als adenosinrezeptorantagonisten
DE60112791D1 (de) Piperidin mch antagonisten und ihre verwendung in der behandlung von obesität
DE60144334D1 (de) Myostatin-antagonisten und Verwendungen davon
EP1608318A4 (en) CXCR4 ANTAGONISTS AND METHOD OF USE
DE60235492D1 (de) Beta-amino-alpha-cyanoacrylate und deren verwendung als herbizide
DE60224194D1 (de) Arzneizusammensetzungen enthaltend terbinafin und deren verwendung
ATE319308T1 (de) Kombinationen von cyclohexandionoxim-herbiziden und safeners
DE60114413D1 (de) Substituierte 1-aminoalkyl-lactame und deren verwendung als muscarinrezeptor-antagonisten
DK1558595T3 (da) Piperazinyl- og diazapanylbenzamider og -benzthioamider
ATE364575T1 (de) Zeolithe und deren verwendung
DE60230245D1 (de) Wabenkonstruktion und deren zusammenbau
ITMI20021247A1 (it) Antagonisti basici non peptidici della bradichinina e loro impiego informulazioni farmaceutiche
DE60302107D1 (de) Saure Öl-in-Wasser emulgierte Zusammensetzungen und deren Verwendung
DE69915113D1 (de) 5ht1 rezeptor antagonisten und ihre verwendung für die behandlung von depression
DE60238174D1 (de) Fluoropolymere und Herstellungs- und Verwendungsverfahren

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1363897

Country of ref document: EP

REN Ceased due to non-payment of the annual fee